Drug Pipeline & Clinical Trials at 39th ECNP Congress
8 sessions on drug pipeline & clinical trials · October 10–13, 2026, Munich, Germany. Compare drug pipeline & clinical trials at other meetings →
Saturday, October 10
Symposium
S01 – Clinical trials across psychiatric disorders: the good, bad and the ugly
Argyris Stringaris · Christian Otte · Heidi Taipale · Blanca Bolea-Alamanac
Critical look at psychiatric trial design, generalizability, and digital therapeutics, including who gets excluded from RCTs.
Symposium
S03 – Breaking Hot Topic Symposium – showcasing the timeliest science – Altered immune function in psychiatric disorders and their treatment
Boris B. Quednow · Sinead King · Jenny Borkent · Anthony Vernon · Cynthia Fu
Late-breaking findings on immune dysfunction in psychiatry, including the MEMOCYCLINE trial, microbiome-guided treatment, and immune-ageing phenotypes of depression.
Sunday, October 11
Plenary
PL02 – ECNP Neuropsychopharmacology Award Lecture – How will we get novel medicines in psychiatry? Lessons from schizophrenia
Award lecture drawing lessons from schizophrenia drug development for the broader pipeline of novel psychiatric medicines.
Symposium
S07 – Engineering mental health: targeted therapies to restore brain and brain-barrier function
Marianne Mueller · Stefan Liebner · Matthew Campbell · Karen Aboody
Blood-brain barrier biology as a therapeutic target, plus stem-cell-derived vesicles and focused ultrasound approaches.
Symposium
MS02 – Proof-of-concept studies showcasing biomarker potential
Leanne Williams · Daniel Gehrlach
Stratified precision-medicine trials, including an alpha-2a agonist for the cognitive biotype of depression and phase 2 results for the vasopressin 1b antagonist nelivaptan.
Session
Panel discussion – The innovation gap in mental health treatments – EU MIC
Andreas Reif · Concha Caudevilla Asensio · Åsa Konradsson-Geuken · Shaun Johnson
Panel on Europe's lag in psychiatric drug innovation, access delays, and paths to bring pharmaceutical innovation back.
Monday, October 12
Symposium
S15 – Novel Therapies Symposium – showcasing clinical trials on emerging compounds and new medical devices
Lone Baandrup · Viktoria Damgaard · Daniel Umbricht · Susan L. Rossell · Alexandra Philipsen · Mikołaj Matłoka
Trial results on emerging treatments including cannabidiol vs risperidone for cannabis-related psychosis (CANRISE), a novel oral NMDA antagonist, PDE10A inhibition in schizophrenia, and digital devices.
Course
CS03 – ECNP Neuroscience Research course session – from preclinical validity to real-world impact
Anton Y. Bespalov · Simone Macri · Janko Samardzic · Patricia Kabitzke
Course on internal and external validity of preclinical data and communicating neuropsychopharmacology to the public.
Other topics at this meeting
Neuroscience & Mechanisms 23Digital Psychiatry & AI 7Pharmacogenomics & Precision Psychiatry 7Inflammation & Immunopsychiatry 6Schizophrenia & Psychosis 6Child & Adolescent 5Depression 5Autism & Neurodevelopmental Disorders 4Neuromodulation (ECT, TMS) 4OCD & Related Disorders 4ADHD 3Practice, Policy & Workforce 3